Key result
YM337 prevents occlusive thrombus formation in a monkey model, unlike aspirin and sodium ozagrel.
Why the study?
Does YM337 inhibit platelet aggregation and prevent thrombus formation in monkey models compared to aspirin or sodium ozagrel?
Population
Rhesus monkeys and squirrel monkeys (photochemically-induced thrombosis model)
Comparison
YM337 via intravenous bolus injection and… vs Aspirin 17 mg/kg intravenous bolus, sodium…
Design
Preclinical
Follow-up
Up to 6 hours
Authors
Loading...
YM337 merits human thrombosis trials; leaves open superiority to aspirin or ozagrel in patients.
Does YM337 inhibit platelet aggregation and prevent thrombus formation in monkey models compared to aspirin or sodium ozagrel?
YM337, a short-acting anti-GPIIb/IIIa monoclonal antibody fragment, effectively inhibits platelet aggregation and prevents occlusive thrombus formation in monkey models.
Kaku et al. (1996) studied Thrombosis. YM337 vs. Aspirin, sodium ozagrel, or saline was evaluated on Time to occlusive thrombus formation. YM337 prevented occlusive thrombus formation in a monkey thrombosis model, whereas aspirin and sodium ozagrel did not significantly change the time to occlusion compared with saline.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: